Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer

  title={Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer},
  author={Benjamin H. L. Tan and Laura Birdsell and Lisa Martin and Vickie E. Baracos and Kenneth C. H. Fearon},
  journal={Clinical Cancer Research},
  pages={6973 - 6979}
Purpose: The average weight-losing pancreatic cancer patient undergoing palliative therapy is frequently overweight rather than underweight, and this can confound conventional measures used for risk stratification. The aim of this study was to evaluate if weight and body composition, specifically sarcopenia, assessed from diagnostic computed tomography (CT) scans, is of prognostic value in patients with pancreatic cancer. The nature and extent of tissue loss over subsequent months was also… 

Figures and Tables from this paper

Nutritional assessment in overweight and obese patients with metastatic cancer: does it make sense?

Findings support that a significant percentage of overweight or obese cancer patients may be at nutritional risk and this is moreover related with adverse prognosis.

Sarcopenia as a Prognostic Index of Nutritional Status in Concurrent Cirrhosis and Hepatocellular Carcinoma

Sarcopenia is present in almost one third of patients with HCC, and constitutes a strong and independent risk factor for mortality, highlighting the importance of body composition assessment in clinical practice.

Are sarcopenia, obesity and sarcopenic obesity predictive of outcome in patients with colorectal liver metastases?

Sarcopenia, obesity and sarcopenic obesity did not worsen DFS, OS and complication rates after a partial liver resection for CRLM, and obesity seemed to prolong OS.

Body Composition, Symptoms, and Survival in Advanced Cancer Patients Referred to a Phase I Service

Background Body weight and body composition are relevant to the outcomes of cancer and antineoplastic therapy. However, their role in Phase I clinical trial patients is unknown. Methods We reviewed

Sarcopenia as an independent prognostic factor in patients following surgery for gallbladder cancer

Intervention to prevent muscle wasting might be an effective strategy for improving the outcome of GBC, and sarcopenia is an independent prognostic factor.

Characterising the impact of body composition change during neoadjuvant chemotherapy for pancreatic cancer.

Body Composition as a Prognostic Factor of Neoadjuvant Chemotherapy Toxicity and Outcome in Patients with Locally Advanced Gastric Cancer

Sarcopenia and sarcopenia were associated with early termination of neoadjuvant chemotherapy in patients with gastric cancer; additionally, sarcopenic obesity was associated with poor survival.

Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study

Sarcopenia is associated with an increased risk of overall mortality in breast cancer survivors and may be associated with breast-cancer-specific mortality, and the development of effective interventions to maintain and/or increase skeletal muscle mass to improve prognosis in cancer survivors warrants further study.



Evaluation of an Inflammation-Based Prognostic Score in Patients with Inoperable Pancreatic Cancer

At diagnosis, the presence of a systemic inflammatory response (as measured by the GPS) appears to be a useful indicator of poor outcome, independent of TNM stage, in patients with inoperable pancreatic cancer.

Obese sarcopenia in patients with end-stage renal disease is associated with inflammation and increased mortality.

PEW is common in overweight ESRD patients and is associated with high FBMI, low LBMI, and inflammation, and PEW was a predictor of mortality in both obese and nonobese sarcopenia patients.

Evaluating body composition of Italian prostate cancer patients without metastases

It was found that lean body mass, but not fat mass, was significantly lower for PCa patients in comparison with healthy controls, and patients with no history of androgen deprivation therapy and no bone metastasis suffer muscle mass depletion.

Changes in nutritional status associated with unresectable pancreatic cancer.

The majority of patients with unresectable pancreatic cancer have already undergone significant weight loss by the time of diagnosis and that the natural history of this process is one of inexorable progression, highlighting the need for selective non-toxic therapeutic intervention to attenuate cachexia.

Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis.

The 3-factor profile (weight loss, reduced food intake, and systemic inflammation) identifies patients with both adverse function and prognosis and applies particularly to cachectic patients with localized disease.

Cachexia Worsens Prognosis in Patients with Resectable Pancreatic Cancer

Cachexia has a significant impact on survival and performance status in palliative patients as well as in patients operated for pancreatic cancer, and that metastatic dedifferentiation of the tumor might be a critical step in the development of tumor-associated cachexia.

Body mass index and mortality in heart failure: a meta-analysis.

Cachexia, survival and the acute phase response

The cause and consequences of the APR in cancer cachexia are explored, which results from anorexia and metabolic change and leads to loss of both adipose tissue and lean body mass, particularly in the skeletal muscle compartment.